Connor, Clark & Lunn Investment Management Ltd. Anavex Life Sciences Corp. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 10, 2022	BUY	$8.9 - $12.86 $712,044 - $1.03 Million	80,005 Added 472.79%	96,927 $1 Million
Q2 2022 Aug 05, 2022	BUY	$7.31 - $12.84 $123,699 - $217,278	16,922 New	16,922 $169,000

Others Institutions Holding AVXL

# of Institutions

155

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

Black Rock Inc. New York, NY

6.39M
Shares

$55.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.74M
Shares

$40.9 Million
0.0% of portfolio
State Street Corp Boston, MA

3.07M
Shares

$26.5 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.88M
Shares

$16.3 Million
0.0% of portfolio
Wealthgarden F.S. LLC El Segundo, CA

910K
Shares

$7.86 Million
0.32% of portfolio

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account